Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free CAI Stock Alerts

Caris Life Sciences (CAI) Financials

Caris Life Sciences logo
$15.55 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$15.56 +0.01 (+0.10%)
As of 05/22/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Caris Life Sciences

Annual Income Statements for Caris Life Sciences

This table shows Caris Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -463 -378 -538
Consolidated Net Income / (Loss)		 -341 -282 -68
Net Income / (Loss) Continuing Operations		 -341 -282 -68
Total Pre-Tax Income 		-341 -282 -68
Total Operating Income		 -320 -257 45
Total Gross Profit		 89 179 539
Total Revenue		 306 412 812
Operating Revenue		 306 412 812
Total Cost of Revenue		 217 233 273
Operating Cost of Revenue		 217 233 273
Total Operating Expenses		 409 436 494
Selling, General & Admin Expense		 149 169 225
Marketing Expense		 143 153 168
Research & Development Expense		 117 114 102
Total Other Income / (Expense), net		 -22 -25 -113
Interest Expense		 32 50 57
Interest & Investment Income		 11 7.12 16
Other Income / (Expense), net		 -1.51 18 -73
Income Tax Expense		 0.00 0.00 0.00
Preferred Stock Dividends Declared		 121 96 470
Basic Earnings per Share		 ($13.24) ($10.66) ($3.22)
Weighted Average Basic Shares Outstanding		 34.94M 35.50M 167.21M
Diluted Earnings per Share		 ($13.24) ($10.66) ($3.22)
Weighted Average Diluted Shares Outstanding		 34.94M 35.50M 167.21M
Weighted Average Basic & Diluted Shares Outstanding		 - - 282.58M

Quarterly Income Statements for Caris Life Sciences

This table shows Caris Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -90 -92 -127 -517 24 -0.51
Consolidated Net Income / (Loss)		 -66 -68 -103 -72 24 -0.51
Net Income / (Loss) Continuing Operations		 -66 -68 -103 -72 24 -0.51
Total Pre-Tax Income 		-66 -68 -103 -72 24 -0.64
Total Operating Income		 -67 -61 -58 -18 33 5.28
Total Gross Profit		 38 44 57 114 148 141
Total Revenue		 100 102 121 181 217 216
Operating Revenue		 100 102 121 181 217 216
Total Cost of Revenue		 62 57 64 68 69 75
Operating Cost of Revenue		 62 57 64 68 69 75
Total Operating Expenses		 105 105 115 132 115 136
Selling, General & Admin Expense		 41 41 52 64 52 60
Marketing Expense		 39 37 40 42 41 45
Research & Development Expense		 25 28 23 25 22 31
Total Other Income / (Expense), net		 0.83 -6.89 -45 -54 -8.32 -5.93
Interest Expense		 14 14 13 19 14 13
Interest & Investment Income		 2.64 1.74 0.50 1.62 7.36 6.83
Other Income / (Expense), net		 12 5.17 -32 -36 -2.17 0.05
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 -0.13
Preferred Stock Dividends Declared		 24 25 24 445 0.00 0.00
Basic Earnings per Share		 ($2.54) ($2.59) ($3.57) ($7.97) $0.09 $0.00
Weighted Average Basic Shares Outstanding		 35.37M 35.64M 35.62M 64.92M 282.10M 282.56M
Diluted Earnings per Share		 ($2.54) ($2.59) ($3.57) ($7.97) $0.08 $0.00
Weighted Average Diluted Shares Outstanding		 35.37M 35.64M 35.62M 64.92M 297.21M 282.56M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 281.22M 282.15M 282.68M

Annual Cash Flow Statements for Caris Life Sciences

This table details how cash moves in and out of Caris Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -51 8.02 732
Net Cash From Operating Activities		 -276 -245 83
Net Cash From Continuing Operating Activities		 -276 -245 83
Net Income / (Loss) Continuing Operations		 -341 -282 -68
Consolidated Net Income / (Loss)		 -341 -282 -68
Depreciation Expense		 49 49 23
Amortization Expense		 5.38 7.05 13
Non-Cash Adjustments To Reconcile Net Income		 18 9.79 149
Changes in Operating Assets and Liabilities, net		 -7.13 -29 -33
Net Cash From Investing Activities		 215 53 -16
Net Cash From Continuing Investing Activities		 215 53 -16
Purchase of Property, Plant & Equipment		 -22 -8.44 -16
Purchase of Investments		 -63 0.00 0.00
Sale and/or Maturity of Investments		 300 61 0.00
Net Cash From Financing Activities		 10 200 665
Net Cash From Continuing Financing Activities		 10 200 665
Repayment of Debt		 -182 0.00 -4.00
Repurchase of Common Equity		 0.00 -1.06 -7.82
Issuance of Debt		 191 200 28
Issuance of Preferred Equity		 0.00 0.00 121
Issuance of Common Equity		 0.00 0.00 539
Other Financing Activities, net		 1.12 1.37 -11
Effect of Exchange Rate Changes		 0.06 - 0.13
Cash Interest Paid		 16 49 44

Quarterly Cash Flow Statements for Caris Life Sciences

This table details how cash moves in and out of Caris Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -71 -41 -33 34 43 23
Net Cash From Operating Activities		 -69 -39 -31 62 45 33
Net Cash From Continuing Operating Activities		 -69 -41 -31 62 45 33
Net Income / (Loss) Continuing Operations		 -68 -37 -103 24 82 -0.51
Consolidated Net Income / (Loss)		 -68 -37 -103 24 82 -0.51
Depreciation Expense		 11 9.07 7.05 4.87 4.29 5.07
Amortization Expense		 1.83 1.91 1.95 2.46 0.61 2.62
Non-Cash Adjustments To Reconcile Net Income		 3.65 -7.82 49 17 17 17
Changes in Operating Assets and Liabilities, net		 -17 -6.97 13 14 -59 8.29
Net Cash From Investing Activities		 -1.83 -2.29 -2.69 -7.10 -5.09 -10
Net Cash From Continuing Investing Activities		 -1.83 -2.29 -2.69 -7.10 -5.09 -10
Purchase of Property, Plant & Equipment		 -1.83 -2.29 -2.69 -7.10 -5.09 -10
Net Cash From Financing Activities		 0.09 0.23 1.29 -21 3.40 0.82
Net Cash From Continuing Financing Activities		 0.09 0.23 1.29 -21 3.40 0.82
Repurchase of Common Equity		 -0.54 -0.03 -0.13 -5.67 -0.09 0.00
Other Financing Activities, net		 0.63 0.25 1.41 -15 3.49 0.82
Effect of Exchange Rate Changes		 - - 0.00 - - -0.01

Annual Balance Sheets for Caris Life Sciences

This table presents Caris Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025
Period end date 12/31/2024 12/31/2025
Total Assets		 344 1,126
Total Current Assets		 216 998
Restricted Cash		 - 798
Short-Term Investments		 2.20 2.30
Accounts Receivable		 88 112
Inventories, net		 40 64
Prepaid Expenses		 20 22
Plant, Property, & Equipment, net		 68 63
Total Noncurrent Assets		 60 65
Goodwill		 19 19
Other Noncurrent Operating Assets		 41 45
Total Liabilities & Shareholders' Equity		 344 1,126
Total Liabilities		 621 548
Total Current Liabilities		 165 127
Short-Term Debt		 60 0.17
Accounts Payable		 28 39
Accrued Expenses		 78 88
Total Noncurrent Liabilities		 455 421
Long-Term Debt		 319 379
Other Noncurrent Operating Liabilities		 136 42
Commitments & Contingencies		 0.00 0.00
Total Equity & Noncontrolling Interests		 -2,499 577
Total Preferred & Common Equity		 -2,499 577
Preferred Stock		 0.00 0.00
Total Common Equity		 -2,499 577
Common Stock		 0.04 3,142
Retained Earnings		 -2,472 -2,549
Accumulated Other Comprehensive Income / (Loss)		 0.21 0.94
Other Equity Adjustments		 -26 -17

Quarterly Balance Sheets for Caris Life Sciences

This table presents Caris Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2025 9/30/2025 3/31/2026
Total Assets		 955 985 1,162
Total Current Assets		 833 854 1,014
Cash & Equivalents		 - 755 821
Short-Term Investments		 2.25 2.27 2.32
Accounts Receivable		 51 27 91
Inventories, net		 41 49 76
Prepaid Expenses		 19 21 24
Plant, Property, & Equipment, net		 61 64 83
Total Noncurrent Assets		 60 66 66
Goodwill		 19 19 19
Other Noncurrent Operating Assets		 41 47 46
Total Liabilities & Shareholders' Equity		 955 985 1,162
Total Liabilities		 502 506 569
Total Current Liabilities		 90 86 144
Short-Term Debt		 0.10 0.16 0.17
Accounts Payable		 29 29 70
Accrued Expenses		 61 57 74
Total Noncurrent Liabilities		 412 420 425
Long-Term Debt		 374 376 381
Other Noncurrent Operating Liabilities		 38 44 44
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 453 478 593
Total Preferred & Common Equity		 453 478 593
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 453 478 593
Common Stock		 3,124 3,125 3,159
Retained Earnings		 -2,655 -2,631 -2,549
Treasury Stock		 -17 -17 -17
Accumulated Other Comprehensive Income / (Loss)		 0.67 0.75 0.89

Annual Metrics And Ratios for Caris Life Sciences

This table displays calculated financial ratios and metrics derived from Caris Life Sciences' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 282,146,923.00
DEI Adjusted Shares Outstanding		 0.00 0.00 282,146,923.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.91
Growth Metrics		 - - -
Profitability Metrics		 - - -
Net Operating Profit after Tax (NOPAT)		 -224 -180 32
Return On Investment Capital (ROIC_SIMPLE)		 - 8.49% 3.30%
Earnings before Interest and Taxes (EBIT)		 -321 -239 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -267 -183 7.65
Valuation Ratios		 - - -
Leverage & Solvency		 - - -
Liquidity Ratios		 - - -
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -215 -90
Efficiency Ratios		 - - -
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 35 156
Increase / (Decrease) in Invested Capital		 0.00 35 122
Book Value per Share		 $0.00 ($70.40) $2.05
Tangible Book Value per Share		 $0.00 ($70.94) $1.98
Total Capital		 0.00 102 956
Total Debt		 0.00 380 379
Total Long-Term Debt		 0.00 319 379
Net Debt		 0.00 312 -421
Capital Expenditures (CapEx)		 22 8.44 16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 43 71
Debt-free Net Working Capital (DFNWC)		 0.00 110 871
Net Working Capital (NWC)		 0.00 50 871
Net Nonoperating Expense (NNE)		 118 102 100
Net Nonoperating Obligations (NNO)		 0.00 312 -421
Total Depreciation and Amortization (D&A)		 54 56 35
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.22)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 167.21M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.22)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 167.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 282.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -224 -180 32
Debt Service Ratios		 - - -
Payout Ratios		 - - -

Quarterly Metrics And Ratios for Caris Life Sciences

This table displays calculated financial ratios and metrics derived from Caris Life Sciences' official financial filings.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 281,224,124.00 282,579,919.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 281,224,124.00 282,579,919.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 0.09 0.00
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 81.31% 113.38% 78.78%
EBITDA Growth		 0.00% 0.00% 0.00% 1.73% 187.28% 116.01%
EBIT Growth		 0.00% 0.00% 0.00% 1.73% 154.73% 105.90%
NOPAT Growth		 0.00% 0.00% 0.00% 73.16% 176.64% 109.11%
Net Income Growth		 0.00% 0.00% 0.00% -8.47% 135.92% 99.50%
EPS Growth		 0.00% 0.00% 0.00% -213.78% 103.09% 100.00%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% 189.91% 204.91%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 1.57% 0.00% 0.00% 19.53% 0.00%
EBITDA Q/Q Growth		 0.00% 21.46% 0.00% 0.00% 169.75% 0.00%
EBIT Q/Q Growth		 0.00% -0.95% 0.00% 0.00% 156.22% 0.00%
NOPAT Q/Q Growth		 0.00% 9.21% 0.00% 0.00% 359.22% 0.00%
Net Income Q/Q Growth		 0.00% -2.33% 0.00% 0.00% 133.88% 0.00%
EPS Q/Q Growth		 0.00% -1.97% 0.00% 0.00% 101.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 19.48% 0.00% 0.00% -26.58%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 44.06% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -5.87% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 37.54% 43.70% 47.19% 62.67% 68.03% 65.39%
EBITDA Margin		 -55.13% -42.63% -67.25% -29.88% 17.44% 6.02%
Operating Margin		 -66.98% -59.87% -47.93% -9.92% 15.05% 2.44%
EBIT Margin		 -55.13% -54.79% -74.68% -29.88% 14.05% 2.47%
Profit (Net Income) Margin		 -66.15% -66.65% -84.84% -39.58% 11.22% -0.24%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 79.19%
Interest Burden Percent		 120.01% 121.65% 113.60% 132.45% 79.83% -12.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 20.47%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 22.38%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% -16.66%
Return on Equity (ROE)		 0.00% 0.00% 0.00% 0.00% 0.00% 3.81%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 1.92%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -0.18%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% 0.00% 0.00% 3.81%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -47 -43 -41 -13 33 3.70
NOPAT Margin		 -46.88% -41.91% -33.55% -6.94% 15.05% 1.71%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -33.93% -4.37% -1.90%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -1.52% 3.82% 0.38%
Cost of Revenue to Revenue		 62.46% 56.30% 52.81% 37.33% 31.97% 34.61%
SG&A Expenses to Revenue		 41.05% 40.20% 43.10% 35.48% 23.97% 27.62%
R&D to Revenue		 24.77% 27.20% 19.08% 13.81% 9.97% 14.49%
Operating Expenses to Revenue		 104.51% 103.58% 95.12% 72.59% 52.97% 62.94%
Earnings before Interest and Taxes (EBIT)		 -55 -56 -90 -54 30 5.33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -55 -43 -81 -54 38 13
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 3.83 18.79 8.51
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 4.00 19.59 8.80
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 5.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 13.33 88.03 30.41
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 5.08
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 45.21
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 67.90
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 42.38
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 31.28
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.83 0.79 0.64
Long-Term Debt to Equity		 0.00 0.00 0.00 0.82 0.79 0.64
Financial Leverage		 0.00 0.00 0.00 -0.77 -0.80 -0.74
Leverage Ratio		 0.00 0.00 0.00 2.11 2.06 1.96
Compound Leverage Factor		 0.00 0.00 0.00 2.79 1.64 -0.24
Debt to Total Capital		 0.00% 0.00% 0.00% 45.21% 44.04% 39.13%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.01% 0.02% 0.02%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 45.20% 44.02% 39.12%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 54.79% 55.96% 60.87%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 3.74
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -4.33
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 3.74
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 3.51
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -4.06
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 3.51
Altman Z-Score		 0.00 0.00 0.00 0.00 0.00 3.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 0.00 0.00 9.24 9.93 7.05
Quick Ratio		 0.00 0.00 0.00 0.59 9.11 6.35
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -117 -65 -148
Operating Cash Flow to CapEx		 0.00% -3,797.98% -1,165.41% 0.00% 879.85% 317.89%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -6.07 -4.83 -11.55
Operating Cash Flow to Interest Expense		 0.00 -5.03 -2.45 0.00 4.62 2.57
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -5.16 -2.66 0.00 4.10 1.76
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.78
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 10.02
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 3.72
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 10.98
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 4.07
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 36.41
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 98.10
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 89.76
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 44.76
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 0.00 0.00 104 98 152
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 11.97
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 104 98 152
Enterprise Value (EV)		 0.00 0.00 0.00 1,386 8,610 4,610
Market Capitalization		 494 494 494 1,735 8,991 5,052
Book Value per Share		 $0.00 $0.00 $0.00 $6.98 $1.70 $2.10
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $6.68 $1.63 $2.03
Total Capital		 0.00 0.00 0.00 827 855 975
Total Debt		 0.00 0.00 0.00 374 376 382
Total Long-Term Debt		 0.00 0.00 0.00 374 376 381
Net Debt		 0.00 0.00 0.00 -349 -381 -442
Capital Expenditures (CapEx)		 0.00 1.83 2.69 0.00 7.10 10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 21 11 47
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 743 768 870
Net Working Capital (NWC)		 0.00 0.00 0.00 743 768 870
Net Nonoperating Expense (NNE)		 19 25 62 59 8.32 4.21
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -349 -381 -442
Total Depreciation and Amortization (D&A)		 0.00 12 8.99 0.00 7.33 7.69
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 5.18%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 95.94%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 95.92%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($7.97) $0.09 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 64.92M 282.10M 282.56M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($7.97) $0.08 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 64.92M 297.21M 282.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 281.22M 282.15M 282.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -47 -43 -41 -13 23 3.70
Normalized NOPAT Margin		 -46.88% -41.91% -33.55% -6.94% 10.54% 1.71%
Pre Tax Income Margin		 -66.15% -66.65% -84.84% -39.58% 11.22% -0.30%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -4.03 -4.03 -7.06 -2.82 2.26 0.42
NOPAT to Interest Expense		 -3.43 -3.09 -3.17 -0.66 2.42 0.29
EBIT Less CapEx to Interest Expense		 0.00 -4.17 -7.28 0.00 1.73 -0.39
NOPAT Less CapEx to Interest Expense		 0.00 -3.22 -3.38 0.00 1.89 -0.52
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 22.65%

Financials Breakdown Chart

Key Financial Trends

Below are key takeaways from Caris Life Sciences (CAI) quarterly statements covering the last four quarters available (2024 Q3–2025 Q4). The bullets focus on indicators that may influence investors, with positive items listed first, then neutral, then negative.

  • Revenue growth in 2025: 2025 Q3 total revenue reached $216,833,000, up from $101,620,000 in 2024 Q3 (roughly a 113% year-over-year increase), signaling a meaningful expansion in top-line activity.
  • Operating cash flow turns positive in 2025: Net cash from continuing operating activities was $62,425,000 in 2025 Q3, indicating improved cash generation from core operations.
  • Continued positive cash flow into Q4 2025: Net cash from continuing operating activities remained positive at $44,780,000 in 2025 Q4, reinforcing the cash-generation trend.
  • Balance sheet growth in 2025 Q3: Total assets increased to $984,571,000 (from $955,058,000 in 2025 Q2), reflecting a larger asset base.
  • Equity base expands in 2025 Q3: Total equity climbed to $478,364,000 in 2025 Q3, up from $452,904,000 in 2025 Q2, contributing to a stronger balance sheet position.
  • Deficit narrowing in 2025 Q3: Retained earnings improved modestly, narrowing the accumulated deficit from $(2,655,018,000) in 2025 Q2 to $(2,630,693,000) in 2025 Q3.
  • Financing activity adds small cash inflow in 2025 Q3: Net cash from continuing financing activities was $3,399,000 in 2025 Q3, providing a modest liquidity boost from financing activities.
  • Investing cash outflows are modest and stabilizing: Cash used for purchases of property, plant, and equipment remained small (e.g., $7,095,000 in 2025 Q3 and $5,090,000 in 2025 Q4), with consistent but manageable investing outflows.
  • Debt levels show small increases: Short-term debt rose to $164,000 and long-term debt to $376,296,000 in 2025 Q3 (up modestly from 2025 Q2), indicating incremental leverage without large jumps.
  • Historical net losses through mid-2025: Net income attributable to common shareholders remained negative through 2025 Q2 and Q3 (approximately -$517.2 million in those quarters), though results swing positive by 2025 Q4, highlighting a volatile profitability trajectory.
05/26/26 02:29 AM ETAI Generated. May Contain Errors.

Caris Life Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Caris Life Sciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Caris Life Sciences' net income appears to be on a downward trend, with a most recent value of -$68.09 million in 2025, falling from -$341.42 million in 2023. The previous period was -$281.89 million in 2024. Check out Caris Life Sciences' forecast to explore projected trends and price targets.

Caris Life Sciences' total operating income in 2025 was $45.11 million, based on the following breakdown:
  • Total Gross Profit: $539.17 million
  • Total Operating Expenses: $494.06 million

Over the last 2 years, Caris Life Sciences' total revenue changed from $306.13 million in 2023 to $812.03 million in 2025, a change of 165.3%.

Caris Life Sciences' total liabilities were at $548.36 million at the end of 2025, a 11.7% decrease from 2024, and a 11.7% decrease since 2024.

Over the last 2 years, Caris Life Sciences' book value per share changed from 0.00 in 2023 to 2.05 in 2025, a change of 204.6%.


Related Companies

Financial statements for NASDAQ:CAI last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel